top of page
Clinical Trial
Clemastine Treatment in Individuals With Williams Syndrome
The clinical trial investigates the safety and efficacy of a potential new treatment for Williams syndrome, targeting improved myelination.
Building on Prof. Barak's research, which highlighted the effectiveness of clemastine (an FDA-approved drug) in enhancing myelination and neurobiological features in a relevant mouse model, this study aims to assess safety and effectiveness in enhancing the quality of life for individuals with Williams syndrome. Special attention will be given to addressing social, motor, and cognitive abnormalities.
Location: Israel
Start date: April 2024
Estimated completion date: December 2025
We believe in the power of science to improve lives, and your support helps us achieve our mission. ​
Research funds are limited, especially for rare diseases, while costs continue to rise.
Every amount makes a difference!
Every donation helps and brings us one step closer to improve the understanding and treatment of Williams syndrome and autism.​​​​
bottom of page